Japanese pharma firm Takeda has announced that the gut-selective biologic vedolizumab when taken as a subcutaneous (SC) injection, proved efficacious in comparison to placebo in patients suffering from moderately to severely active ulcerative colitis (UC). The therapy was proven effective in the Phase III VISIBLE 1 clinical trial in which 46.2% of patients given vedolizumab, compared to 14.3% of those given a placebo achieved clinical remission.
![Design thinking als contentmarketeer inzetten [voorbeelden & tips]](https://www.pharmamarketeer.nl/wp-content/uploads/2024/11/business-team-working-in-a-start-up-office-2023-11-27-05-22-22-utc-1-80x60.jpg)
Reageer